Oops. Did we say that "Montreal-based Valeant Pharmaceuticals is buying Long Beach, Calif.-based specialty pharma company Obagi Medical Products for about $344 million" -- a price of only 2.9 times sales, versus Valeant's own 6.2 P/S ratio?

What we meant to say was that Valeant was hoping it could get the shares at such a nice discount. Turns out, though, that someone else is willing to bid quite a bit more for Obagi. That someone emerged this morning, when Germany's Merz Pharmaceuticals sent Obagi's board a letter offering to buy the same stock for 11% more -- $22 a share.

Merz calls its offer a "superior proposal" to the one Valeant tendered last month. Merz says it's also ready to buy right away, needs to perform no additional due diligence, and has the cash in hand to make the buy "immediately" -- all of which has to make this a very tempting offer for Obagi.


For its part Obagi's board confirmed this morning that it's received Merz's offer and will "evaluate" it with the understanding that "time is of the essence." Expect a reply soon.

The article Merz Pharma Outbids Valeant for Obagi originally appeared on Fool.com.

Fool contributor Rich Smith and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Reading a Stock Quote

Learn to read the ingredients of a stock.

View Course »

Basics of Diversification

Learn one of the fundamental concepts of building a portfolio.

View Course »

Add a Comment

*0 / 3000 Character Maximum